International Urogynecology Journal

, Volume 27, Issue 6, pp 919–922 | Cite as

Dry eye findings worsen with anticholinergic therapy in patients with urge incontinence

  • Zuhal Ozen Tunay
  • Ozdemir Ozdemir
  • Damla Ergintürk Acar
  • Sabri Cavkaytar
  • Ebru Ersoy
Original Article


Introduction and hypothesis

To evaluate the effects of oral anticholinergic (OAC) drugs on tear secretion in women with overactive bladder over a 3-month follow-up period.


In this prospective study, 108 women with a diagnosis of overactive bladder were evaluated. All patients were examined ophthalmologically at baseline (day 0), and after 1 month (day 30) and 3 months (day 90) of OAC treatment. Tear film break-up time (BUT) and Schirmer 1 test results were recorded. The subjective complaints of the patients including dry mouth, and burning, dryness and foreign body sensation in the eyes, were also recorded. The chi-squared test or the paired sample t test as appropriate, was used for statistical analysis.


The mean age of the patients was 51.8 ± 9.2 years (30 – 69 years). The most frequent subjective complaints were dry mouth and dry eyes and both complaints were significant on both day 30 and day 90. Both tear film BUT and Schirmer 1 test results were significantly lower on day 30 and day 90. Dry eye measurement values worsened with prolongation of OAC treatment (p = 0.037 and p = 0.012 for BUT, and p = 0.046 and p = 0.035 for Schirmer 1 test, on day 30 and day 90, respectively).


OAC treatment in women with overactive bladder significantly and progressively affects tear secretion.


Anticholinergic therapy Dry eye Overactive bladder 


  1. 1.
    Gani J, Perlis N, Radomski SB (2012) Urologic medications and ophthalmologic side effects: a review. Can Urol Assoc J 6:53–58PubMedPubMedCentralGoogle Scholar
  2. 2.
    Feinberg M (1993) The problems of anticholinergic adverse effects in older patients. Drugs Aging 3:335–348CrossRefPubMedGoogle Scholar
  3. 3.
    Cetinel B, Onal B (2013) Rationale for the use of anticholinergic agents in overactive bladder with regard to central nervous system and cardiovascular system side effects. Korean J Urol 54:806–815CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Chapple CR, Nilvebrant L (2002) Tolterodine: selectivity for the urinary bladder over the eye (as measured by visual accommodation) in healthy volunteers. Drugs R D 3:75–81CrossRefPubMedGoogle Scholar
  5. 5.
    Lachkar Y, Bouassida W (2007) Drug-induced acute angle closure glaucoma. Curr Opin Ophthalmol 18:129–133CrossRefPubMedGoogle Scholar
  6. 6.
    Abrams P, Andersson KE, Buccafusco JJ, Chapple C, Chet de Groat W, Fryer AD, Kay G, Laties A, Nathanson NM, Pasricha PJ, Wein AJ (2006) Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol 148:565–578CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Lemp MA (2008) Advances in understanding and managing dry eye disease. Am J Ophthalmol 146:350–356CrossRefPubMedGoogle Scholar
  8. 8.
    Kato K, Furuhashi K, Suzuki K, Murase T, Sato E, Gotoh M (2007) Overactive bladder and glaucoma: a survey at outpatient clinics in Japan. Int J Urol 14:595–597CrossRefPubMedGoogle Scholar
  9. 9.
    Eskandar OS, Eckford SD, Whittaker KW (2005) Treatment of overactive bladder (OBA) with anti-cholinergic drugs and the risk of glaucoma. J Obstet Gynaecol 25:419–421CrossRefPubMedGoogle Scholar
  10. 10.
    Yaycioglu RA, Yaycioglu O, Akova YA, Guvel S, Ozkardeş H (2005) Ocular side-effects of tolterodine and oxybutynin, a single-blind prospective randomized trial. Br J Clin Pharmacol 59:588–592CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Sekeroglu MA, Hekimoglu E, Petricli IS, Tasci Y, Dolen I, Arslan U (2014) The effect of oral solifenacin succinate treatment on intraocular pressure: glaucoma paradox during overactive bladder treatment. Int Urogynecol J 25:1479–1482CrossRefPubMedGoogle Scholar
  12. 12.
    Yayla EM, Yavuz E, Bilge U, Keskin A, Binen E (2015) Drugs with anticholinergic side-effects in primary care. Niger J Clin Pract 18(1):18–21PubMedGoogle Scholar
  13. 13.
    Wong J, Lan W, Ong LM, Tong L (2011) Non-hormonal systemic medications and dry eye. Ocul Surf 9:212–226CrossRefPubMedGoogle Scholar

Copyright information

© The International Urogynecological Association 2015

Authors and Affiliations

  • Zuhal Ozen Tunay
    • 1
    • 3
  • Ozdemir Ozdemir
    • 1
  • Damla Ergintürk Acar
    • 1
  • Sabri Cavkaytar
    • 2
  • Ebru Ersoy
    • 2
  1. 1.Ophthalmology DepartmentZekai Tahir Burak Women’s Health Education and Research HospitalAnkaraTurkey
  2. 2.Urogynecology DepartmentZekai Tahir Burak Women’s Health Education and Research HospitalAnkaraTurkey
  3. 3.Göz Hastalıkları PolikliniğiZekai Tahir Burak Kadın Sağlığı Eğitim ve Araştırma HastanesiAnkaraTurkey

Personalised recommendations